REGENXBIO (NASDAQ:RGNX) Stock Rating Upgraded by StockNews.com

REGENXBIO (NASDAQ:RGNXGet Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

RGNX has been the subject of a number of other reports. Royal Bank of Canada upgraded shares of REGENXBIO from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $20.00 to $35.00 in a research report on Friday, March 8th. Stifel Nicolaus restated a “buy” rating and set a $40.00 target price on shares of REGENXBIO in a research report on Friday, April 12th. The Goldman Sachs Group started coverage on REGENXBIO in a report on Friday, June 7th. They issued a “buy” rating and a $38.00 price target on the stock. Wedbush reiterated a “neutral” rating and set a $21.00 price target on shares of REGENXBIO in a research report on Wednesday, February 28th. Finally, Raymond James restated an “outperform” rating and issued a $45.00 price objective on shares of REGENXBIO in a research report on Wednesday, February 21st. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.58.

Check Out Our Latest Stock Report on RGNX

REGENXBIO Stock Up 4.9 %

Shares of NASDAQ RGNX opened at $12.21 on Tuesday. The company has a market cap of $601.46 million, a P/E ratio of -2.08 and a beta of 1.34. REGENXBIO has a 52 week low of $11.56 and a 52 week high of $28.80. The business has a 50-day simple moving average of $15.33 and a two-hundred day simple moving average of $17.26.

REGENXBIO (NASDAQ:RGNXGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.10). The firm had revenue of $15.60 million during the quarter, compared to analysts’ expectations of $23.52 million. REGENXBIO had a negative return on equity of 70.72% and a negative net margin of 299.96%. The company’s quarterly revenue was down 18.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.53) earnings per share. Equities research analysts anticipate that REGENXBIO will post -3.9 EPS for the current year.

Insider Activity at REGENXBIO

In other REGENXBIO news, CEO Kenneth T. Mills sold 15,000 shares of REGENXBIO stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $15.81, for a total transaction of $237,150.00. Following the transaction, the chief executive officer now directly owns 408,035 shares of the company’s stock, valued at $6,451,033.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.13% of the stock is currently owned by insiders.

Institutional Trading of REGENXBIO

Several institutional investors have recently added to or reduced their stakes in RGNX. PNC Financial Services Group Inc. lifted its stake in shares of REGENXBIO by 73.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 746 shares during the last quarter. ProShare Advisors LLC lifted its position in REGENXBIO by 8.3% in the first quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after purchasing an additional 874 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of REGENXBIO by 2.0% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,549 shares of the biotechnology company’s stock valued at $889,000 after purchasing an additional 990 shares during the period. Texas Permanent School Fund Corp grew its holdings in shares of REGENXBIO by 3.2% in the third quarter. Texas Permanent School Fund Corp now owns 34,333 shares of the biotechnology company’s stock worth $565,000 after purchasing an additional 1,051 shares during the last quarter. Finally, Amalgamated Bank increased its stake in shares of REGENXBIO by 7.3% in the third quarter. Amalgamated Bank now owns 16,559 shares of the biotechnology company’s stock worth $273,000 after buying an additional 1,133 shares during the period. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

About REGENXBIO

(Get Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Recommended Stories

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.